Fidelity Investments
DSGN icon

Fidelity Investments’s Design Therapeutics DSGN Stock Holding History

Fidelity Investments’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.5M Buy
798,411
+27,143
+4% +$275K ﹤0.01% 2103
2025
Q4 		$7.23M Buy
771,268
+30,419
+4% +$238K ﹤0.01% 2153
2025
Q3 		$5.58M Sell
740,849
-210,349
-22% -$1.05M ﹤0.01% 2205
2025
Q2 		$3.21M Buy
951,198
+3,148
+0.3% +$11.8K ﹤0.01% 2321
2025
Q1 		$3.66M Sell
948,050
-3,832
-0.4% -$18.3K ﹤0.01% 2258
2024
Q4 		$5.87M Buy
951,882
+123,217
+15% +$713K ﹤0.01% 2100
2024
Q3 		$4.46M Buy
828,665
+747,649
+923% +$3.52M ﹤0.01% 2164
2024
Q2 		$271K Buy
81,016
+2,675
+3% +$10.4K ﹤0.01% 2934
2024
Q1 		$316K Sell
78,341
-671
-0.8% -$1.79K ﹤0.01% 2867
2023
Q4 		$209K Buy
79,012
+8,954
+13% +$20.5K ﹤0.01% 2952
2023
Q3 		$165K Sell
70,058
-567,712
-89% -$2.65M ﹤0.01% 2945
2023
Q2 		$4.02M Sell
637,770
-320,133
-33% -$1.96M ﹤0.01% 2121
2023
Q1 		$5.53M Sell
957,903
-161,634
-14% -$1.21M ﹤0.01% 2060
2022
Q4 		$11.5M Buy
1,119,537
+36,675
+3% +$497K ﹤0.01% 1835
2022
Q3 		$18.1M Buy
1,082,862
+55,922
+5% +$1.11M ﹤0.01% 1645
2022
Q2 		$14.4M Sell
1,026,940
-426
-0% -$5.75K ﹤0.01% 1791
2022
Q1 		$16.6M Buy
1,027,366
+27,366
+3% +$419K ﹤0.01% 1870
2021
Q4 		$21.4M Hold
1,000,000
– – ﹤0.01% 1796
2021
Q3 		$14.7M Hold
1,000,000
– – ﹤0.01% 1967
2021
Q2 		$19.9M Hold
1,000,000
– – ﹤0.01% 1850
2021
Q1 		$29.9M Buy
+1,000,000
New +$33.7M ﹤0.01% 1620

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments's DSGN Position: Q1 2026 in Review

Fidelity Investments increased its Design Therapeutics (DSGN) stake by 3.5% in Q1 2026, buying an estimated $275K and bringing the position to 798,411 shares worth $8.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2103.

Fidelity Investments first reported a position in DSGN in Q1 2021 and has held it in 21 quarters since. The position peaked at $29.9M in Q1 2021. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Fidelity Investments held 798,411 shares of Design Therapeutics worth $8.5M as of Q1 2026.
  • Fidelity Investments bought 27,143 Design Therapeutics shares in Q1 2026, an estimated $275K.
  • Design Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2103 holding.
  • Fidelity Investments first reported a position in Design Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Fidelity Investments's Design Therapeutics position peaked at $29.9M in Q1 2021.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.